Future-proof your post Brexit Pharmacovigilance.

If you are based in the UK, hold an MA in the UK, or have your EU QPPV in the UK you will be affected by the UK’s decision to leave the EU, also known as Brexit.

Pure Drug Safety has formed a strategic partnership with a leading PV service provider in Europe that allows our extended highly experienced team to help you meet your legal requirements post Brexit.

Benefits of using Pure Drug Safety for your post Brexit pharmacovigilance:
• Two Companies / One Team
• Highly trained and experienced team of PV professionals
• Maintain licences in EU and UK post Brexit
• Act as local (UK based) contact for MHRA
• PSMF and back up service in Europe
• Able to provide gap analysis for clients to identify risks and opportunities

Call us now on +44(0) 1476 512395 and let our UK and European team help you meet your legal pharmacovigilance requirements post Brexit.

To read more about Pharmacovigilance (QPPV) post Brexit, click here.

As at 23 October 2020, the situation regarding a Deal or No Deal Brexit is extremely fluid. As such, rather than bombard you with our guesses and interpretations of what may or may not happen, we would rather give you direct links to the MHRA latest guidance HERE and also the EMA latest guidance HERE on Brexit so you can see for yourself what the latest information available is. However, at present, please be aware that this guidance is currently aimed at a deal for Brexit being agreed. Please check back regularly for more updates as we have them.